US Food and Drug Administration (USFDA) has completed the inspection at Ipca Laboratories’ Formulations manufacturing Unit situated at Piparia (Silvassa). The agency has conducted operations from August 19, 2019 to August 23, 2019. At the conclusion of the inspection, the USFDA issued a Form 483 with 3 observations.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.